Tauriga IP Acquisition

Tauriga Sciences is a diversified life sciences company specializing in the development and commercialization of cannabinoid-based products. The company's primary focus is its proprietary Tauri-Gum™ line, a CBD and CBG-infused supplement chewing gum designed for various wellness applications. Through its subsidiary, Tauriga Pharma Corp. (formerly known as Tauriga IP Acquisition Corp.), the company is advancing a pharmaceutical-grade version of its medicated chewing gum to treat chemotherapy-induced nausea. Tauriga Sciences is publicly traded and actively seeks to expand its portfolio through intellectual property acquisitions and strategic partnerships in the biotechnology and consumer healthcare sectors.